Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Recruiting now NCT05530096
Run by Sir Mortimer B. Davis - Jewish General Hospital · for 18 and older · All sexes
What this study is about
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Confirmed MM diagnosis
- Transplant eligible patients in a first remission
- Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
- Availability of deidentified patient's demographic and clinical follow up data
- Receiving standard of care treatment
- Able to provide informed consent
🚫 You may not be able to join if…
- Failure to meet inclusion criteria
Where this trial is running
- Jewish General Hospital, Montreal, Quebec, Canada
Who to contact
Rayan Kaedbey, MD FRCPC · 514-340-8222 · rayan.kaedbey.med@ssss.gouv.qc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05530096.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.